Functional characterization of vasopressin receptor 2 mutations causing partial and complete congenital nephrogenic diabetes insipidus in thai families

Hormone Research in Paediatrics

Volumn 73, Issue 5, 2010, Pages 349-354

  Sahakitrungruang, Taninee ^a,b   Tee, Meng Kian ^b   Rattanachartnarong, Natthakorn ^a   Shotelersuk, Vorasuk ^a   Suphapeetiporn, Kanya ^a   Miller, Walter L ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AVPR2; G protein; Mutation analysis; Polyuria

Indexed keywords

1 DESAMINO 8 DEXTRO ARGININE VASOPRESSIN; ARGIPRESSIN; ELECTROLYTE; HYDROCHLOROTHIAZIDE; UNCLASSIFIED DRUG; VASOPRESSIN;

ARTICLE; AVPR2 GENE; CASE REPORT; CHILD; GENE; GENE SEQUENCE; HUMAN; MALE; MISSENSE MUTATION; NEPHROGENIC DIABETES INSIPIDUS; POLYDIPSIA; POLYURIA; PRESCHOOL CHILD; PRIORITY JOURNAL; THAILAND; URINE; WATER DEPRIVATION;

ARGININE VASOPRESSIN; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CELL LINE; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; DIABETES INSIPIDUS, NEPHROGENIC; HUMANS; INFANT; KIDNEY CONCENTRATING ABILITY; MALE; MUTATION; MUTATION, MISSENSE; RECEPTORS, VASOPRESSIN; TRANSFECTION;

EID: 77954057911     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000308167     Document Type: Article

References (30)

1. van Lieburg AF, Knoers N V, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1999; 10:1958-1964.
2. Morello JP, Bichet DG: Nephrogenic diabetes insipidus. Annu Rev Physiol 2001; 63: 607-630.
3. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W: Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357: 333-335.
4. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S: Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993; 361: 549-552.
5. Robben JH, Knoers N V, Deen PM: Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physi-ol Renal Physiol 2006; 291:F257-F270.
6. Spanakis E, Milord E, Gragnoli C: AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol 2008; 217: 605-617.
7. Sadeghi H, Robertson GL, Bichet DG, In-na morat i G, Birnbaumer M: Biochem ica l basis of partial nephrogenic diabetes insipidus phenotypes. Mol Endocrinol 1997; 11:1806-1813.
8. Ala Y, Morin D, Mouillac B, Sabatier N, Vargas R, Cotte N, Dechaux M, Antignac C, Ar-thus MF, Lonergan M, Turner MS, Balestre M N, A lonso G, H iber t M, B a rber is C, Hendy GN, Bichet DG, Jard S: Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol 1998; 9: 1861-1872.
9. Vargas-Poussou R, Forestier L, Dautzenberg MD, Niaudet P, Dechaux M, Antignac C: Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997; 8:1855-1862. (Pubitemid 28185443)
10. Pasel K, Schulz A, Timmermann K, Linnemann K, Hoeltzenbein M, Jaaskelai-nen J, Gruters A, Filler G, Schoneberg T: Functional characterization of the molecular defects causing nephrogenic diabetes in-sipidus in eight families. J Clin Endocrinol Metab 2000; 85: 17 0 3-17 10.
11. Inaba S, Hatakeyama H, Taniguchi N, Mi-yamori I: The property of a novel V2 receptor mutant in a patient with nephrogenic diabetes insipidus. J Clin Endocrinol Metab 2001; 86:381-385.
12. Chen CH, Chen WY, Liu HL, Liu TT, Tsou AP, Lin CY, Chao T, Qi Y, Hsiao KJ: Identification of mutations in the arginine vasopres-sin receptor 2 gene causing nephrogenic diabetes insipidus in Chinese patients. J Hum Genet 2002; 47: 66-73.
13. Faerch M, Christensen JH, Corydon TJ, Kamperis K, de Zegher F, Gregersen N, Robertson GL, Rittig S: Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene. Clin Endocrinol (Oxf) 2008; 68:395-403.
14. Robben JH, Knoers NV, Deen PM: Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. Am J Physiol Renal Physiol 2005; 289:F265-F272.
15. Feldman BJ, Rosenthal SM, Vargas GA, Fen-wick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE: Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352:1884-1890.
16. Ranadive SA, Ersoy B, Favre H, Cheung CC, Rosenthal SM, Miller WL, Vaisse C: Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin En-docrinol (Oxf) 2009; 71: 388-393.
17. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P: Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106:253-262.
18. Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C: The binding site of neuro-peptide vasopressin V1a receptor. Evidence for a major localization within transmem-brane regions. J Biol Chem 1995; 270:25771-25777.
19. Derick S, Pena A, Durrou x T, Wag non J, Ser-radeil-Le Gal C, Hibert M, Rognan D, Guil-lon G: Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor. Mol Endocri-nol 2004; 18: 2777-2789.
20. Rodrigo J, Pena A, Murat B, Trueba M, Dur-roux T, Guillon G, Rognan D: Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors. Mol Endo-crinol 2007; 21: 51 2-5 2 3.
21. Saito M, Tahara A, Sugimoto T: 1-Desami-no-8-D-arginine vasopressin (dDAVP) as an agonist on V1b vasopressin receptor. Bio-chem Pharmacol 1997; 53:1711-1717.
22. Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Ols s on R, Piu F: Ident if ic at ion of nove l se-lective V2 receptor non-peptide agonists. Biochem Pharmacol 2008; 76: 11 3 4-114 1.
23. Albertazzi E, Zanchetta D, Barbier P, Faran-d a S, Frat t i ni A, Vezz on i P, P ro c a c c io M, B et-tinelli A, Guzzi F, Parenti M, Chini B: Neph-rogenic diabetes insipidus: Functional analysis of new AVPR2 mutations identified in Italian families. J Am Soc Nephrol 2000; 11:1033-1043.
24. Pan Y, Wilson P, Gitschier J: The effect of eight V2 vasopressin receptor mutations on stimulation of adenylyl cyclase and binding to vasopressin. J Biol Chem 1994; 269:31933-31937.
25. Fujiwara TM, Morgan K, Bichet DG: Molecular biology of diabetes insipidus. Annu Rev Med 1995; 46: 331-34 3.
26. Schulz A, Grosse R, Schultz G, Gudermann T, Schoneberg T: Structural implication for receptor oligomerization from functional reconstitution studies of mutant V2 vaso-pressin receptors. J Biol Chem 2000; 275: 2381-2389.
27. Labrou NE, Bhogal N, Hurrell CR, Findlay JB: Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. J Biol Chem 2001; 276:37944-37949.
28. Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D: Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildena-fil citrate (viagra). Am J Physiol Renal Physiol 2005; 288:F1103-F1112.
29. Robben JH, Sze M, Knoers NV, Deen PM: Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochap-erones: relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2007; 292:F253-F260.
30. Morello JP, Salahpour A, Laperriere A, Bern i er V, A r t hu s M F, L o nerg a n M, Pet aj a-Re p o U, A ngers S, Mor i n D, Biche t DG, Bouv ier M: Pharmacological chaperones rescue cell-surface expression and function of misfold-ed V2 vasopressin receptor mutants. J Clin Invest 2000; 105: 887-895.